Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. (2021)
Attributed to:
Respiratory infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02717-3
PubMed Identifier: 34863358
Publication URI: http://europepmc.org/abstract/MED/34863358
Type: Journal Article/Review
Volume: 398
Parent Publication: Lancet (London, England)
Issue: 10318
ISSN: 0140-6736